Dachen Pharmaceutical

Established in 2017, Taizhou Dachen Pharmaceutical was designed and built to meet GMP guidelines, integrating research development and production of APIs and intermediates. It was acquired by Sunrise Group in 2022with a total annual output value of approximately 400 million yuan. Products: 3-trifluoro methyl-[1,2,4]triazole[4,3-a]piperazine hydrochloride, pyrazole, aloeemodin,(3S)-3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydro-furan,(3R,4S,5R,6R)-3,4,5-tris(triMethylsilyloxy)-6-((triMethylsilyloxy)Methyl)tetrahydro-2H-pyran-2-one, sodium hyaluronate, N5-((R)-3-(acetylthio)-1-((carboxymethyl)amino)-1-oxopropan-2-yl)-L-glutamine, etc. As the National High-Tech Enterprise, the company's key products are predominantly demanded in Europe, Southeast Asia, South America, etc.